Omeros Corporation (NASDAQ:OMER – Get Free Report) Director Arnold Hanish sold 10,000 shares of Omeros stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total transaction of $189,500.00. Following the completion of the transaction, the director directly owned 5,000 shares in the company, valued at $94,750. This represents a 66.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Omeros Price Performance
NASDAQ OMER opened at $18.61 on Friday. Omeros Corporation has a 12 month low of $3.94 and a 12 month high of $19.65. The company has a market capitalization of $1.35 billion, a P/E ratio of 14.54 and a beta of 2.54. The company’s 50 day simple moving average is $12.64 and its 200 day simple moving average is $12.03.
Omeros (NASDAQ:OMER – Get Free Report) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. On average, analysts anticipate that Omeros Corporation will post -0.37 earnings per share for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on Omeros
Hedge Funds Weigh In On Omeros
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. HighTower Advisors LLC raised its stake in Omeros by 4.3% during the 2nd quarter. HighTower Advisors LLC now owns 115,368 shares of the biopharmaceutical company’s stock valued at $1,097,000 after purchasing an additional 4,738 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Omeros in the second quarter worth $146,000. California State Teachers Retirement System boosted its position in shares of Omeros by 19,094.9% in the second quarter. California State Teachers Retirement System now owns 720,192 shares of the biopharmaceutical company’s stock worth $75,730,000 after buying an additional 716,440 shares during the period. Compass Financial Management LLC purchased a new position in shares of Omeros during the second quarter valued at $312,000. Finally, Ancora Advisors LLC raised its position in Omeros by 46.7% during the second quarter. Ancora Advisors LLC now owns 168,750 shares of the biopharmaceutical company’s stock valued at $1,605,000 after buying an additional 53,750 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.
About Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Stories
- Five stocks we like better than Omeros
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
